Kimball Electronics (KE) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
5 Nov, 2026Executive summary
Q1 FY27 net sales rose 7% YoY and 5% sequentially to $390.8M, with 3% organic growth, $12.4M from Helvoet, and a 1% favorable FX impact.
Medical was the strongest vertical; FY27 sales guidance was reiterated, with sales expected at the high end of the range.
Reported operating income fell to $12.4M from $14.5M and net income to $2.6M from $10.1M; acquisition costs, higher interest, and withholding taxes weighed on earnings.
Financial highlights
Gross profit was $30.9M versus $28.8M; gross margin held at 7.9%, as favorable mix was offset by higher material costs and the Indianapolis medical CDMO ramp.
Adjusted operating income was $17.0M, or 4.3% of sales, versus $17.5M, or 4.8%; adjusted EBITDA increased to $27.6M from $26.7M.
Adjusted net income was $6.1M versus $12.3M; adjusted diluted EPS was $0.25 versus $0.49. The tax-rate difference accounted for $0.12 per share of EPS variance.
Selling and administrative expense rose 38% to $18.1M, including $2.0M of Helvoet acquisition costs and higher acquired-intangible amortization; prior-year expense included a $2.0M customer cost recovery.
The 66.1% effective tax rate included $3.0M of withholding taxes on dividends used partly to fund Helvoet; the prior-year 8.3% rate benefited from OBBA-related tax benefits.
Outlook and guidance
FY27 sales guidance remains $1.535B–$1.560B, with sales expected at the high end, supported by Medical strength.
FY27 adjusted operating income guidance is 4.4%–4.7% of sales; capital expenditure guidance is $50M–$60M.
Helvoet contribution is expected to ramp through FY27; Indianapolis production is expected to begin in December, with integration on schedule and budget.
An additional $1.0M–$2.5M of restructuring costs is expected through FY27; no further plan charges are anticipated after FY27.
Operating cash generation and available borrowing capacity are expected to meet working-capital and other operating needs for at least the next 12 months.
Latest events from Kimball Electronics
- Medical CDMO expansion anchors FY27 growth and margin ambitions.KE
Corporate presentation - Key votes include director elections, auditor ratification, and a proposed company name change.KE
Proxy filing - Shareholders to vote on director elections, auditor, executive pay, and rebranding to Kimball Solutions.KE
Proxy filing - Shareholders to vote on directors, auditor, executive pay, and a rebrand amid strong performance.KE
Proxy filing - Q4 growth and margin gains set up a 7–9% FY27 outlook, driven by medical and Helvoet.KE
Q4 2026 - Medical segment growth and new facility drive raised outlook and margin expansion plans.KE
2026 KeyBanc Capital Markets Healthcare Forum - Acquisition expands global medical CMO platform, boosting growth and earnings by 2027.KE
M&A announcement - Profitable growth expected as medical and automotive markets drive margin expansion and investment.KE
Company presentation - Q1 FY2025 sales fell 15% as restructuring and asset sales improved cash flow and reduced debt.KE
Q1 2025